Howard Feldman

Professor

University of California, San Diego

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Howard Feldman is a Professor at the University of California, San Diego. His research focuses on the prevention and treatment of Alzheimer's disease, with recent publications addressing risk stratification, implementation strategies for dementia prevention programs, and pharmacological assessments in Alzheimer's care. He has also contributed to studies on the effects of exercise on cognitive health and the development of web-based tools for dementia literacy. His work aims to enhance understanding and intervention strategies in neurodegenerative conditions, particularly within diverse populations.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (7)

Alfred Fonteh

Associate Professor, Lab. Director

Huntington Medical Research Institutes

UNITED STATES

View details

Ging-Yuek Hsiung

The University of British Columbia

CANADA

View details

David Knopman

Professor

Mayo Clinic Rochester

UNITED STATES

View details

Nicolas Villain

Sorbonne Université

FRANCE

View details

January Durant

University of California, San Diego

UNITED STATES

View details

Sachin Pandey

CANADA

View details

Richard Camicioli

Associate/Full Professor

University of Alberta

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Howard Feldman

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial

An International Working Group viewpoint on stratifying risk and prevention of the clinical expression of Alzheimer’s disease

Brain health PRO/Santé cerveau PRO: The development of a web-based program for dementia literacy and risk factor reduction

Tailoring implementation strategies for the healthy actions and lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program: Lessons learned from a survey study

Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research

Effects of exercise on cognition and Alzheimer's biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study

Effects of exercise versus usual care on older adults with amnestic mild cognitive impairment: EXERT versus ADNI

IWG and AA Criteria - Where the Differences Matter - Reply

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective

Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam)

Clinical value of Alzheimer's disease biomarker testing

Optimal Weighting of Preclinical Alzheimer’s Cognitive Composite (PACC) Scales to Improve their Performance as Outcome Measures for Alzheimer’s Disease Clinical Trials

Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias

Multidomain trials to prevent dementia: addressing methodological challenges

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease

Exploring Social Cognition Tests to Differentiate Frontotemporal Dementia from Depression

Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome

CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease

Home EEG sleep assessment shows reduced slow‐wave sleep in mild–moderate Alzheimer's disease

T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease

Impact of potential modifications to Alzheimer's disease clinical trials in response to disruption by COVID-19: a simulation study.

Collaborators (7)

Alfred Fonteh

Ging-Yuek Hsiung

David Knopman

Nicolas Villain

January Durant

Sachin Pandey

Richard Camicioli

Make your next move.